Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S5QB
|
||||
| Former ID |
DNC003608
|
||||
| Drug Name |
KYS-05040
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H31N5O
|
||||
| Canonical SMILES |
C1CCN(CC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=<br />C(C=C5)N
|
||||
| InChI |
1S/C28H31N5O/c29-22-15-13-21(14-16-22)20-30-27(34)19-26-24-11-5-6-12-25(24)31-28(32-17-7-2-8-18-32)33(26)23-9-3-1-4-10-23/h1,3-6,9-16,26H,2,7-8,17-20,29H2,(H,30,34)
|
||||
| InChIKey |
NEMYASVJMUEWED-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent T-type calcium channel alpha-1G subunit | Target Info | Inhibitor | [1] | |
| Voltage-dependent T-type calcium channel subunit alpha-1H | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| Circadian entrainment | |||||
| Type II diabetes mellitushsa04010:MAPK signaling pathway | |||||
| PANTHER Pathway | Endogenous cannabinoid signaling | ||||
| GABA-B receptor II signaling | |||||
| Nicotine pharmacodynamics pathway | |||||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| PathWhiz Pathway | Muscle/Heart ContractionPW000564:Muscle/Heart Contraction | ||||
| Reactome | NCAM1 interactionsR-HSA-419037:NCAM1 interactions | ||||
| WikiPathways | NCAM signaling for neurite out-growth | ||||
| Nicotine Activity on Chromaffin CellsWP2355:Corticotropin-releasing hormone | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.